Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Sep 15:476:123641.
doi: 10.1016/j.jns.2025.123641. Epub 2025 Aug 5.

Characteristics and causes of recurrent ischemic events in minor ischemic stroke and TIA in the READAPT study

Federico De Santis  1 Matteo Foschi  1 Michele Romoli  2 Tiziana Tassinari  3 Valentina Saia  3 Silvia Cenciarelli  4 Chiara Bedetti  4 Chiara Padiglioni  4 Bruno Censori  5 Valentina Puglisi  5 Luisa Vinciguerra  5 Maria Guarino  6 Valentina Barone  6 Maria Luisa Zedde  7 Ilaria Grisendi  7 Marina Diomedi  8 Maria Rosaria Bagnato  8 Marco Petruzzellis  9 Domenico Maria Mezzapesa  9 Pietro Di Viesti  10 Vincenzo Inchingolo  10 Manuel Cappellari  11 Mara Zenorini  11 Paolo Candelaresi  12 Vincenzo Andreone  12 Giuseppe Rinaldi  13 Alessandra Bavaro  13 Anna Cavallini  14 Stefan Moraru  14 Pietro Querzani  15 Maria Grazia Piscaglia  15 Valeria Terruso  16 Marina Mannino  16 Umberto Scoditti  17 Alessandro Pezzini  18 Giovanni Frisullo  19 Francesco Muscia  20 Maurizio Paciaroni  21 Maria Giulia Mosconi  22 Andrea Zini  23 Ruggiero Leone  24 Carmela Palmieri  25 Letizia Maria Cupini  26 Michela Marcon  27 Rossana Tassi  28 Enzo Sanzaro  29 Cristina Paci  30 Giovanna Viticchi  31 Daniele Orsucci  32 Anne Falcou  33 Simone Beretta  34 Roberto Tarletti  35 Patrizia Nencini  36 Eugenia Rota  37 Federica Nicoletta Sepe  38 Delfina Ferrandi  38 Luigi Caputi  39 Gino Volpi  40 Salvatore La Spada  41 Mario Beccia  42 Claudia Rinaldi  43 Vincenzo Mastrangelo  43 Francesco Di Blasio  44 Paolo Invernizzi  45 Giuseppe Pelliccioni  46 Maria Vittoria De Angelis  47 Laura Bonanni  48 Giampietro Ruzza  49 Emanuele Alessandro Caggia  50 Monia Russo  51 Agnese Tonon  52 Maria Cristina Acciarri  53 Sabrina Anticoli  54 Cinzia Roberti  55 Giovanni Manobianca  56 Gaspare Scaglione  56 Francesca Pistoia  1 Alberto Fortini  57 Antonella De Boni  58 Alessandra Sanna  59 Alberto Chiti  60 Leonardo Barbarini  61 Marcella Caggiula  61 Maela Masato  62 Massimo Del Sette  63 Francesco Passarelli  64 Maria Roberta Bongioanni  65 Danilo Toni  66 Stefano Ricci  67 Eleonora De Matteis  68 Simona Sacco  69 Raffaele Ornello  1 READAPT Study Group
Affiliations
Free article
Observational Study

Characteristics and causes of recurrent ischemic events in minor ischemic stroke and TIA in the READAPT study

Federico De Santis et al. J Neurol Sci. .
Free article

Abstract

Background and purpose: Understanding the causes of recurrent ischemic events in patients with minor stroke or high-risk TIA is crucial to understand unmet needs in secondary prevention. This study examines the characteristics and causes of recurrences after non-cardioembolic minor stroke/high-risk TIA in patients treated with the best medical care.

Methods: This subgroup analysis from a prospective real-world study (READAPT, NCT05476081) included patients with non-cardioembolic minor ischemic stroke (NIHSS ≤5) or TIA (ABCD2 score ≥ 4), receiving short-term DAPT. We described the etiologic distribution according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification of the index and of the recurrent event. We analyzed baseline characteristics of patients with and without a 90-day ischemic recurrence to identify factors linked to recurrence.

Results: Out of 1641 patients, 56 (3.4 %) had a recurrent ischemic event (35 strokes and 21 TIAs). The cause of recurrences was undetermined in 21 (37.5 %), small vessel occlusion in 18 (32.1 %), large artery atherosclerosis in 11 (19.6 %), other determined in 3 (5.4 %), and cardioembolism in 3 (5.4 %). The etiologic distribution of recurrent events differed from that of the corresponding index events (p = 0.002). Non-compliance to DAPT was more prevalent in patients with recurrences compared with those without (8.9 % vs 3.7 %, p = 0.048).

Conclusions: Patients with recurrences after a minor stroke or high-risk TIA have a different etiologic distribution compared with their index events. Additionally, a lower compliance to DAPT was observed in those with recurrences, suggesting that adherence to DAPT should be encouraged to optimize the outcome of patients.

Keywords: Dual antiplatelet therapy; Ischemic stroke; Secondary prevention; Stroke etiopathogenesis; Transient ischemic attack.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Piscaglia reports grants from Sanofi Genzyme; grants from Roche Health Solutions Inc.; grants from Novartis Pharma; grants from Biogen; and grants from Merck Company Foundation. Dr. Paciaroni reports compensation from Boehringer Ingelheim for other services; compensation from PFIZER CANADA INC for other services; compensation from Bristol-Myers Squibb for other services; compensation from iRhythm Technologies for other services; compensation from SANOFIAVENTIS U.S. LLC for other services; and compensation from Daiichi Sankyo Europe GmbH for other services. Dr. Zini reports compensation from Bayer Healthcare for other services; compensation from Boehringer Ingelheim for consultant services; compensation from Alexion Pharmaceuticals for consultant services; and compensation from CSL Behring for consultant services. Dr. Ornello reports grants from Novartis; compensation from Teva Pharmaceutical Industries for other services; compensation from AbbVie for data and safety monitoring services; compensation from Teva Pharmaceutical Industries for other services; compensation from Eli Lilly and Company for other services; compensation from Novartis for other services; compensation from H. Lundbeck AS for other services; compensation from Eli LIlly for data and safety monitoring services; grants from Pfizer; grants from Allergan; travel support from Teva Pharmaceutical Industries; and compensation from Teva Pharmaceutical Industries for consultant services. Prof Sacco reports compensation from Novartis for other services; compensation from Novo Nordisk for consultant services; compensation from Boehringer Ingelheim for consultant services; compensation from Teva Pharmaceutical Industries for consultant services; compensation from Allergan for consultant services; employment by Università degli Studi dell'Aquila; compensation from Novartis for consultant services; compensation from Allergan for consultant services; compensation from PFIZER CANADA INC for consultant services; compensation from Abbott Canada for consultant services; compensation from H. Lundbeck A S for consultant services; compensation from AstraZeneca for consultant services; and compensation from Eli Lilly and Company for consultant services. The other authors report no conflicts.

Publication types

Substances

LinkOut - more resources